Until a decade ago, it was believed that the number of insulin-producing cells that one is born with, is the total number one has for a lifetime. We now know that a small percentage of insulin-producing beta cells are housed within a structure known as the Islets of Langerhans. The population of beta cells expands and contracts with our dietary habits. The islets in which they are housed also die and are regenerated at a very slow rate of turnover.
CureDM’s novel Human proIslet Peptide (HIP) is hypothesized to stimulate and enhance the islet regeneration process that occurs naturally to create new structures that house a new pool of insulin- producing cells from the precursor cells in adult pancreatic tissue. As new islets are formed, not only is the secretion of insulin restored, but also, other hormones that are missing among type 1 diabetes patients, such as amylin, are also restored. In addition, the physiological control for these important hormones is also restored.
Our research is based on the concept of Islet Neogenesis, which has the potential for reversal of diabetes.
The benefits of this approach are:
- No embryonic stem cell research required
- Involves naturally occurring human proteins
- No global immune suppression such as that required for islet transplants
- Uses specific targeted immune agents designed solely to block the attacking antibodies found in type 1 diabetes patients, which have been shown to preserve islets
- Restores pancreatic islet function and glycemic control resulting in normal glucose metabolism
- Restores production of other islet hormones deficient or missing in type 1 diabetes
- This new therapy will apply to both newly diagnosed type 1 and longstanding diabetes, as well as type 2 patients who require insulin.
Type 1 Diabetes
Type 2 Diabetes